Pulmicort Asthma Prevention (Post-PAC)

AstraZeneca

Status: Completed

Conditions: Asthma

Treatments: Procedure: Pulmicort (budesonide) pMDI

Study type: Interventional

Funder types: Industry

Identifiers

NCT00233584

D5254C00004

Details and patient eligibility

About

This prospective study will evaluate the feasibility of the defined decision tree for the treatment of asthmatic young children. Children who develop episode (=3 consecutive days) of any troublesome lower respiratory symptoms are treated according to a strictly pre-defined multi-steps treatment algorithm until the age of 6 years.

Sex: All

Ages: Under 6 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Children form the COPSAC/PAC study with episodes of troublesome respiratory symptoms. Episodes are defined as 3 consecutive days of any troublesome lower respiratory symptoms.

Exclusion criteria

• Differential diagnoses including at least a chest x-ray and sweat test.

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)